An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

  • End date
    Mar 21, 2021
  • participants needed
  • sponsor
    Jazz Pharmaceuticals
Updated on 25 November 2020
Associate Director Clinical Trial Disclosure
Primary Contact
Children's National Health System (5.3 mi away) Contact
+61 other location
lymphoid leukemia
lymphoblastic lymphoma


This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL/LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to assess the tolerability and efficacy of JZP-458 (only in patients who develop hypersensitivity to an E. coli-derived asparaginase), as measured by asparaginase activity.

Treatment IM JZP-458, IV JZP-458
Clinical Study IdentifierNCT04145531
SponsorJazz Pharmaceuticals
Last Modified on25 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Gender: Male or Female
Do you have any of these conditions: childhood ALL or Lymphocytic Leukemia, Acute or Lymphoid leukemia?
Do you have any of these conditions: acute lymphoblastic leukemia (all) or Lymphoid leukemia or Lymphocytic Leukemia, Acute or acute lymphoblastic leukemia or acute lymphoid leukaemia or ...?
Do you have any of these conditions: acute lymphocytic leukemia or lymphatic leukaemia or childhood ALL or lymphocytic leukemia or acute lymphoblastic leukemia (all) or lymphoblastic leuk...?
Pediatric and adult patients with a diagnosis of ALL or LBL
Have had an allergic reaction to a long-acting E. coli-derived asparaginase OR have silent inactivation
Have 1 or more courses of E. coli-derived asparaginase remaining in his/her treatment plan
Patients must have, in the opinion of the Investigator, fully recovered from their prior allergic reaction to E. coli-derived asparaginase

Exclusion Criteria

Have previously received asparaginase Erwinia chrysanthemi or JZP-458
Have relapsed ALL or LBL
Are concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP-458 (within 48 hours) during Course 1 of JZP-458
Have a history of Grade 3 pancreatitis
Prior history of asparaginase-associated Grade 3 hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet